Company Update (NASDAQ:AMGN): Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma

[PR Newswire] – THOUSAND OAKS, Calif., Feb. 11, 2015 /PRNewswire/ — Amgen (AMGN) announced today that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) of . . . → Read More: Company Update (NASDAQ:AMGN): Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma Similar Articles: Stock Update (NASDAQ:AMGN): The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide Stock Update (NYSE:BMY): Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency